“You have at least one reader who prefers not to use childish name-calling,” says our contributor today, “like readers you quoted in your last email.

“Democrats are NOT Socialists, though a minority are. Republicans are NOT Fascists, though a minority are.

“I am a capitalist, and a MODERATE Democrat. I listen to lots of opinions from the right and left, but not the hard-right or the hard-left. I don’t blindly follow a political party or even a single source of investment advice.

“My portfolio has benefited from the market’s rise, but I do not attribute gains to positive decisions made by the Trump administration. It’s more despite the Trump administration that’s put the market in a bubble, as a whole.

“Last, I am truly disappointed that our president has magnified our divisions and exploited them, turning us against each other, seemingly for his own benefit or entertainment.”

As we approach Independence Day, what do you see as the divisions among us? And how can Americans come together again?

Send your opinions to,

Your Rundown for Monday, June 29, 2020


One stock to watch — Gilead Sciences (GILD) — is moving up and to the right this morning; shares are up about 2%.

We’ve mentioned the California-based pharmaceutical company on several occasions throughout the fever-dream months of the COVID-19 pandemic.

In January, we noted the company’s robust 4% dividend offering. And exactly two months ago, we brought your attention to drug trials for critically-ill coronavirus patients using Gilead’s antiviral drug remdesivir.

Early results were encouraging. Kathleen Mullane of the University of Chicago, for example, said of the drug trial: “We have seen people come off ventilators a day after starting [remdesivir] therapy. So, in that realm, overall our patients have done very well.”

In response, the FDA expedited emergency approval for remdesivir on May 1, allowing the drug’s use for hospital patients exhibiting “severe symptoms of the disease, such as a need for oxygen or other help breathing,” Business Insider reports.

Early this morning, Gilead’s CEO Daniel O’Day announced remdesivir’s price: $2,340 for government-insured patients or $3,120 for commercially-insured patients — for a five-day course of treatment.

According to the FDA and clinical trials, remdesivir helped COVID-19 patients recuperate 31% faster than those patients who received a placebo.

Not the antidote everyone’s keenly anticipating, but it’s a step in the right direction.

Market Rundown for Monday, Jun. 29, 2020

The S&P 500 futures are up 6 points to 3,012.

Oil stands at $38.74 for a barrel of West Texas crude.

Gold’s up $1.70 per ounce to $1,782.

Bitcoin is down $47 to $9,046.50.

Send your comments and questions to,

Thanks for checking back. We’ll have more to talk about Wednesday.

For the Rundown,

Aaron Gentzler

Aaron Gentzler

You May Also Be Interested In:

Aaron Gentzler

Aaron Gentzler is the publisher of Seven Figure Publishing. He is also the editor of The Rundown and has been with Agora Financial / Seven Figure Publishing since 2005. He's been covering technology and markets for over a decade.

View More By Aaron Gentzler